BPC-157 Shows Protective Effects in Mouse Models of Parkinson's Disease
BPC-157 reduced Parkinson's-like symptoms caused by MPTP and haloperidol in mice while simultaneously protecting their stomachs from damage caused by these same drugs.
Quick Facts
What This Study Found
BPC-157 attenuated both MPTP- and haloperidol-induced Parkinson's-like symptoms in mice while simultaneously protecting against gastric lesions caused by these parkinsongenic agents.
Key Numbers
How They Did This
Animal study in mice using two Parkinson's models: MPTP (30 mg/kg daily for 4 days) and haloperidol. BPC-157 at microgram and nanogram doses was tested for behavioral (motor) and gastroprotective effects.
Why This Research Matters
Parkinson's disease has limited treatment options. A peptide that reduces dopaminergic neuronal damage while protecting the gut (which is also affected in Parkinson's) addresses two aspects of this disease simultaneously.
The Bigger Picture
Parkinson's disease involves both brain and gut pathology. BPC-157's dual neuroprotective and gastroprotective effects align with the emerging understanding of Parkinson's as a gut-brain disorder.
What This Study Doesn't Tell Us
Mouse models don't fully replicate human Parkinson's. MPTP and haloperidol models represent acute dopamine disruption, not chronic neurodegeneration. No direct measurement of dopamine neuron survival.
Questions This Raises
- ?Does BPC-157 protect dopamine neurons directly or modulate downstream signaling?
- ?Could BPC-157 slow Parkinson's progression in chronic models?
- ?Is BPC-157's neuroprotection related to its gut-brain axis effects?
Trust & Context
- Key Stat:
- Dual protection BPC-157 protected both the brain (reducing PD symptoms) and gut (preventing gastric lesions) from parkinsongenic agents simultaneously
- Evidence Grade:
- Preliminary animal evidence from two complementary Parkinson's models showing consistent neuroprotective and gastroprotective effects.
- Study Age:
- Published in 1999. BPC-157's dopaminergic and neuroprotective effects have been studied further, with the gut-brain axis becoming a major focus in Parkinson's research.
- Original Title:
- A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine.
- Published In:
- Journal of physiology, Paris, 93(6), 505-12 (1999)
- Authors:
- Sikiric, P(36), Marovic, A(8), Matoz, W, Anic, T, Buljat, G, Mikus, D, Stancic-Rokotov, D, Separovic, J, Seiwerth, S, Grabarevic, Z, Rucman, R, Petek, M, Ziger, T, Sebecic, B, Zoricic, I, Turkovic, B, Aralica, G, Perovic, D, Duplancic, B, Lovric-Bencic, M, Rotkvic, I, Mise, S, Jagic, V, Hahn, V
- Database ID:
- RPEP-00558
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could BPC-157 help Parkinson's disease?
In mice, BPC-157 reduced Parkinson's symptoms from two different causes. This is early animal evidence, but it suggests BPC-157 may protect dopamine neurons. Human studies would be needed to confirm any benefit.
Why does a gut peptide affect Parkinson's?
Parkinson's disease is increasingly understood as a gut-brain disorder — it may actually start in the gut. A gastric peptide that affects the dopamine system and protects both gut and brain is uniquely positioned for this disease.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00558APA
Sikiric, P; Marovic, A; Matoz, W; Anic, T; Buljat, G; Mikus, D; Stancic-Rokotov, D; Separovic, J; Seiwerth, S; Grabarevic, Z; Rucman, R; Petek, M; Ziger, T; Sebecic, B; Zoricic, I; Turkovic, B; Aralica, G; Perovic, D; Duplancic, B; Lovric-Bencic, M; Rotkvic, I; Mise, S; Jagic, V; Hahn, V. (1999). A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine.. Journal of physiology, Paris, 93(6), 505-12.
MLA
Sikiric, P, et al. "A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine.." Journal of physiology, 1999.
RethinkPeptides
RethinkPeptides Research Database. "A behavioural study of the effect of pentadecapeptide BPC 15..." RPEP-00558. Retrieved from https://rethinkpeptides.com/research/sikiric-1999-a-behavioural-study-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.